Integrating dosimetric and clinical insights: correlating acute bone marrow toxicity with irradiated marrow volume in rectal cancer patients undergoing concurrent chemoradiation

Divya S.; Kunhalankutty C. K.; Prasanth C. C.

doi:10.18203/2320-6012.ijrms20242221

Authors

Divya S. Department of Radiation Oncology, Govt Medical College, Kozhikode, Kerala, India
Kunhalankutty C. K. Department of Radiation Oncology, Govt Medical College, Kozhikode, Kerala, India
Prasanth C. C. Department of Radiation Oncology, Govt Medical College, Kozhikode, Kerala, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20242221

Keywords:

Rectal cancer, Bonemarrow toxicity, Dosimetric parameters, Concurrent chemoradiation

Abstract

Background: Concurrent chemoradiation is one of the major treatments for locally advanced rectal cancer. As radiation therapy suppresses the bone marrow, it is essential to quantify the dose received by the pelvic bone marrow (PBM), which constitutes about 50% of the hematopoietic bone marrow.

Methods: A prospective study conducted in 50 patients with locally advanced rectal cancer treated with long course concurrent chemoradiation. All the patients were followed up with weekly complete blood count for assessing hematological toxicities and were graded. PBM was contoured and subdivided into ilium bone marrow (IBM), lower pelvis bone marrow (LPBM) and lumbosacral bone marrow (LSBM). Volumes of bone marrow receiving different doses were quantified.

Results: Among the 50 patients, 40 (80%) developed acute bone marrow toxicity, during the course of treatment. Highest grade of bone marrow toxicity developed in 20 (40%) patients which was grade 2. Compared to grade 1, grade 2 neutropenia patients exhibited significantly higher levels of V10 to V40 (p<0.05) in PBM and significantly higher levels of V20 in IBM and LSBM. In LPBM, compared to grade 1 leukopenia and neutropenia, grade 2 leukopenia and neutropenia exhibited significantly higher levels of V10 and V20 (p<0.05).

Conclusions: Increased PBM V10 to V40, IBM V20, LSBM V20, LPBM V10 and V20 were significantly related to the higher grades of neutropenia in locally advanced rectal cancer patients undergoing long course concurrent chemoradiation. Increased LPBM V10 and V20 were also significantly related with higher grades of leukopenia.

Metrics

Metrics Loading ...

References

Colorectal Cancer Awareness Month 2022. Available at: https://www.iarc.who.int/featured-news/colorectal-cancer-awareness-month-2022/. Accessed on 12 April 2024.

Consensus document for management of colorectal cancer. 2014. Available at: https://main.icmr.nic.in/sites/default/files/guidelines/Colorectal%20Cancer0.pdf. Accessed on 12 April 2024.

Cohen AM. Adjuvant therapy in rectal cancer. Hepatogastroenterology. 1992 Jun;39(3):215–21.

Garcia-Aguilar J. Transanal endoscopic microsurgery following neoadjuvant chemoradiation therapy in rectal cancer: a word of caution about patient selection? Dis Colon Rectum. 2013;56(1):1-3.

Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery-the clue to pelvic recurrence? Br J Surg. 1982;69(10):613-6.

Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, et al. Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy. Int J Radiat Oncol. 2008;70(5):1431-7.

Li N, Liu X, Zhai F, Liu B, Cao X, Li S, et al. Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy. Oncotarget. 2017;8(54):92904-13.

Shao L, Luo Y, Zhou D. Hematopoietic Stem Cell Injury Induced by Ionizing Radiation. Antioxid Redox Signal. 2014;20(9):1447-62.

Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(5):1356-65.

Hayman J. Distribution of Proliferating Bone Marrow in Adult Cancer Patients Determined Using FLT-PET Imaging. Int J Radiation Oncol Biol Physics. 2011;79(3):847-52.

Wang X, Yu Y, Meng W, Jiang D, Deng X, Wu B, et al. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2018;129(2):300-305.

Feng Y. Comparison of concurrent chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone in stage II/III rectal cancer patients after radical operation. Chin J Radiat Oncol. 2014;23:199-204.

Yamaguchi T, Fukuda M, Yasui H, Okazaki S, Kubo K, Tanaka M, et al. Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients. Gan To Kagaku Ryoho. 2012;39(3):389-93.

Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74(3):824-30.

Lee NY. Target volume delineation for conformal and intensity-modulated radiation therapy. New York, NY: Springer Berlin Heidelberg. 2015.

Yang TJ, Oh JH, Apte A, Son CH, Deasy JO, Goodman KA. Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014;113(1):29-34.

Yang Y, Li W, Qian J, Zhang J, Shen Y, Tian Y. Dosimetric predictors of acute hematologic toxicity due to intensity-modulated pelvic radiotherapy with concurrent chemotherapy for pelvic cancer patients. Transl Cancer Re. 2018;7(3):10.

Kumar T, Schernberg A, Busato F, Laurans M, Fumagalli I, Dumas I, et al. Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation. Cancer Manag Res. 201;11:6285-97.